Hofmann R - Search Results

1

Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.

Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P. Leeming DJ, et al. Among authors: hofmann r. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1269-76. doi: 10.1158/1055-9965.EPI-07-2697. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18483350

2

Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.

Hegele A, Wahl HG, Varga Z, Sevinc S, Koliva L, Schrader AJ, Hofmann R, Olbert P. Hegele A, et al. Among authors: hofmann r. BJU Int. 2007 Feb;99(2):330-4. doi: 10.1111/j.1464-410X.2006.06604.x. Epub 2006 Dec 1. BJU Int. 2007. PMID: 17092281

3

Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.

Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ. Olbert PJ, et al. Among authors: hofmann r. Anticancer Drugs. 2006 Sep;17(8):993-6. doi: 10.1097/01.cad.0000231468.69535.97. Anticancer Drugs. 2006. PMID: 16940810

4

[Evaluation of biochemical bone metabolism parameters].

Hegele A, Olbert P, Wahl HG, Hofmann R. Hegele A, et al. Among authors: hofmann r. Urologe A. 2007 Sep;46(9):1285-6. doi: 10.1007/s00120-007-1390-x. Urologe A. 2007. PMID: 17609924 German. No abstract available.

5

[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].

Olbert PJ, Weil C, Hegele A, Hofmann R, Schrader AJ. Olbert PJ, et al. Among authors: hofmann r. Aktuelle Urol. 2009 May;40(3):164-8. doi: 10.1055/s-0028-1098888. Epub 2009 Apr 15. Aktuelle Urol. 2009. PMID: 19370533 Clinical Trial. German.

6

Cellular fibronectin in patients with transitional cell carcinoma of the bladder.

Hegele A, Heidenreich A, Varga Z, von Knobloch R, Olbert P, Kropf J, Hofmann R. Hegele A, et al. Among authors: hofmann r. Urol Res. 2003 Feb;30(6):363-6. doi: 10.1007/s00240-002-0280-3. Epub 2002 Oct 1. Urol Res. 2003. PMID: 12599015

7

Metastatic renal cell carcinoma: recent advances and current therapeutic options.

Schrader AJ, Hofmann R. Schrader AJ, et al. Among authors: hofmann r. Anticancer Drugs. 2008 Mar;19(3):235-45. doi: 10.1097/cad.0b013e3282f444de. Anticancer Drugs. 2008. PMID: 18510169 Review.

8

[Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker].

Hegele A, Kosche B, Schrader AJ, Sevinc S, Olbert PJ, Hofmann R, Kropf J. Hegele A, et al. Among authors: hofmann r. Urologe A. 2008 Sep;47(9):1137-40. doi: 10.1007/s00120-008-1825-z. Urologe A. 2008. PMID: 18651122 German.

9

Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma.

Hegele A, Heidenreich A, Kropf J, von Knobloch R, Varga Z, Hofmann R, Olbert P. Hegele A, et al. Among authors: hofmann r. Tumour Biol. 2004 May-Jun;25(3):111-6. doi: 10.1159/000079142. Tumour Biol. 2004. PMID: 15361707

10

Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.

Schrader AJ, Heidenreich A, Hegele A, Olbert P, Ohlmann CH, Varga Z, von Knobloch R, Hofmann R. Schrader AJ, et al. Among authors: hofmann r. Anticancer Drugs. 2005 Jun;16(5):581-5. doi: 10.1097/00001813-200506000-00014. Anticancer Drugs. 2005. PMID: 15846124 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

717 results

Search Page

Filters